(S (NP (NP (DT The) (JJ novel) (NN nature)) (PP (IN of) (NP (NNP SARS-CoV-2)))) (VP (NNS calls) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN efficient) (ADJP (IN de) (FW novo)) (NN drug) (NN design) (NNS approaches)))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT an) (JJ end-to-end) (NN framework)) (, ,) (VP (VBN named) (S (NP (NP (NNP CogMol)) (PRN (-LRB- -LRB-) (NP (NP (VBN Controlled) (NNP Generation)) (PP (IN of) (NP (NNP Molecules)))) (-RRB- -RRB-))))) (, ,) (PP (IN for) (S (VP (VBG designing) (NP (NP (JJ new) (JJ drug-like) (JJ small) (NNS molecules)) (VP (VBG targeting) (NP (JJ novel) (JJ viral) (NNS proteins)) (PP (IN with) (NP (NP (JJ high) (NN affinity)) (CC and) (NP (JJ off-target) (NN selectivity))))))))))) (. .))
(S (NP (NNP CogMol)) (VP (NNS combines) (NP (NP (NP (JJ adaptive) (NN pre-training)) (PP (IN of) (NP (NP (DT a) (JJ molecular) (NNP SMILES) (NNP Variational) (NNP Autoencoder)) (PRN (-LRB- -LRB-) (NP (NNP VAE)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT an) (JJ efficient) (ADJP (NN multi-attribute) (VBD controlled)) (VBG sampling) (NN scheme)) (SBAR (WHNP (WDT that)) (S (VP (VBZ uses) (NP (NP (NN guidance)) (PP (IN from) (NP (NP (JJ attribute) (NNS predictors)) (VP (VBD trained) (PP (IN on) (NP (NN latent) (NNS features))))))))))))) (. .))
(S (S (VP (TO To) (VP (VB generate) (NP (NP (ADJP (NN novel) (CC and) (JJ optimal)) (JJ drug-like) (NNS molecules)) (PP (IN for) (NP (JJ unseen) (JJ viral) (NNS targets))))))) (, ,) (NP (NNP CogMol)) (VP (VBZ leverages) (NP (NP (DT a) (JJ protein-molecule) (NN binding) (NN affinity) (NN predictor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN trained) (S (VP (VBG using) (NP (NP (NNP SMILES) (NNP VAE) (NNS embeddings)) (CC and) (NP (NP (JJ protein) (NN sequence) (NNS embeddings)) (VP (VBD learned) (ADVP (JJ unsupervised)) (PP (IN from) (NP (DT a) (JJ large) (NN corpus)))))))))))))) (. .))
(S (NP (NNP CogMol) (NN framework)) (VP (VBZ is) (VP (VBN applied) (PP (TO to) (NP (NP (CD three) (NNP SARS-CoV-2) (NN target) (NNS proteins)) (: :) (NP (NP (JJ main) (NN protease)) (, ,) (NP (NP (JJ receptor-binding) (NN domain)) (PP (IN of) (NP (DT the) (NN spike) (NN protein)))) (, ,) (CC and) (NP (JJ non-structural) (NN protein) (CD 9) (NN replicase))))))) (. .))
(S (NP (DT The) (VBN generated) (NNS candidates)) (VP (VBP are) (ADJP (JJ novel)) (PP (IN at) (NP (DT both) (JJ molecular) (CC and) (JJ chemical) (NN scaffold) (NNS levels))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (DT the) (NN training) (NNS data))))))) (. .))
(S (NP (NNP CogMol)) (ADVP (RB also)) (VP (VBZ includes) (NP (NP (NP (JJ insilico) (VBG screening)) (PP (IN for) (S (VP (VBG assessing) (NP (NP (NN toxicity)) (PP (IN of) (NP (NP (NN parent) (NNS molecules)) (CC and) (NP (PRP$ their) (NNS metabolites))))) (PP (IN with) (NP (DT a) (JJ multi-task) (NN toxicity) (NN classifier))))))) (, ,) (NP (NP (JJ synthetic) (NN feasibility)) (PP (IN with) (NP (DT a) (NN chemical) (NN retrosynthesis) (NN predictor)))) (, ,) (CC and) (NP (NP (NN target) (NN structure) (VBG binding)) (PP (IN with) (NP (VBG docking) (NNS simulations)))))) (. .))
(S (NP (VBG Docking)) (VP (NNS reveals) (NP (NP (JJ favorable) (NN binding)) (PP (IN of) (NP (JJ generated) (NNS molecules))) (PP (TO to) (NP (NP (DT the) (NN target) (NN protein) (NN structure)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NP (CD 87-95) (NN %)) (PP (IN of) (NP (JJ high) (NN affinity) (NNS molecules)))) (VP (VBD showed) (NP (NP (VBG docking) (JJ free) (NN energy)) (NP (NNP <) (NNP -6) (NN kcal/mol)))))))))) (. .))
(S (SBAR (WHADVP (WRB When)) (S (VP (VBN compared) (PP (TO to) (NP (VB approved) (NNS drugs)))))) (, ,) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (VBN designed) (NNS compounds)))) (VP (VBP show) (NP (NP (JJ low) (UCP (NN parent) (NN molecule) (CC and) (JJ metabolite)) (NN toxicity)) (CC and) (NP (JJ high) (JJ synthetic) (NN feasibility)))) (. .))
(S (PP (IN In) (NP (JJ summary))) (, ,) (NP (NNP CogMol)) (VP (VP (VBZ handles) (NP (NP (JJ multi-constraint) (NN design)) (PP (IN of) (NP (NP (JJ synthesizable) (, ,) (JJ low-toxic) (, ,) (JJ drug-like) (NNS molecules)) (PP (IN with) (NP (JJ high) (NN target) (NN specificity) (CC and) (NN selectivity))))))) (, ,) (CC and) (VP (VBZ does) (RB not) (VP (VB need) (NP (NP (JJ target-dependent) (NN fine-tuning)) (PP (IN of) (NP (NP (DT the) (NN framework)) (CC or) (NP (NN target) (NN structure) (NN information)))))))) (. .))
